Certain clauses in the trade deal could dilute use of public health measures under Indian patent law.

MSF technical analysis shares problematic clauses in EFTA India FTA trade agreement

MSF welcomes the Indian Commerce Ministry’s strong stand against the inclusion of data exclusivity in its free trade agreement talks with the European Free Trade Association (EFTA).

Leaked text shows India-EFTA trade deal includes excessive intellectual property provisions that may require India to gut pro-public health national laws, which may undermine people's access to affordable medicines from India

2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.

MSF response to negotiations on an India-EU free trade agreement (FTA) regarding harmful intellectual property (IP) provisions

Ahead of the final hearing on a patent challenge by two TB survivors, MSF urges the Indian Patent Office to reject Johnson & Johnson’s secondary patent application so that other manufacturers may enter the supply chain with more ...

UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely

Up until March 2021, Papua New Guinea had been largely spared of any major COVID-19 outbreak. Within a few weeks, confirmed COVID-19 cases have tripled and increasing numbers of healthcare staff are testing positive, pushing them into ...

Amidst the ongoing global crisis caused by the COVID-19 pandemic, the United States Trade Representative (USTR) released its annual “Special 301 Report” targeting countries for implementing and supporting public health safeguard in ...

Shortages of first-line antibiotics, which are essential to treat a wide range of common infections, are a major public health threat

“India should be cautious while signing any trade package or launching trade negotiations with the US that may include harmful provisions threatening India’s ability to produce and supply affordable medical products. Going by past ...

While we welcome the recent withdrawal of harmful provisions from the IP chapter of RCEP, namely patent term extensions and data exclusivity, Japan’s strong push for elevated IP enforcement measures continues to be a matter of grave ...

Bhakti’s Story: Strength to Survive Drug-Resistant TB

Phumeza and Nandita suffered permanent hearing loss because of toxic drugs used to treat their drug-resistant TB. Now they’re working to ensure that this doesn’t happen to anyone else.

Médecins Sans Frontières (MSF) is supporting a patent challenge filed in India this week by two tuberculosis survivors, to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the tuberculosis drug ...